An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...

Suspect who police say detonated Cybertruck kept ‘activity journal’ for 10 days before attack ...

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

A new study has introduced an innovative approach to CAR-T therapy that could address some of the current challenges in ...

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...